Literature DB >> 11455223

Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.

H Köppler1, J Heymanns, R Weide.   

Abstract

BACKGROUND: Premedication with dexamethasone, ranitidine and clemastine is mandatory for patients receiving paclitaxel to avoid hypersensitivity reactions. The proposed dexamethasone dose is 20 mg orally 12 and 6 h prior to paclitaxel infusion. With this premedication severe hypersensitivity reactions are reduced to 1-2% of the treated patients. Besides this oral schedule a single dose of dexamethasone, 40 mg given i.v., just prior to paclitaxel has been shown to be equally effective. In an attempt to reduce steroid-induced side effects, especially for patients receiving weekly paclitaxel protocols, we reduced the dexamethasone dose. PATIENTS AND METHODS: A total of 132 patients were treated on an outpatient basis with paclitaxel-containing protocols. Paclitaxel was given in doses of 135-175 mg/m(2) once every 3 weeks in 76 patients and/or with 100 mg/m(2) weekly in 70 patients. Dexamethasone premedication was given in a single dose (40, 20, 10 mg) as an infusion directly before paclitaxel.
RESULTS: 0/46 patients receiving 40 mg dexamethasone premedication in 235 cycles and 0/48 patients receiving 20 mg dexamethasone premedication in 186 cycles experienced a severe hypersensitivity reaction. 1/52 patients receiving 10 mg dexamethasone in 480 applications developed a severe hypersensitivity reaction with bronchospasm, hypotension and supraventricular tachycardia shortly after her first paclitaxel infusion started.
CONCLUSION: No increase of severe hypersensitivity reactions is seen when dexamethasone premedication is reduced to doses of 20 or even 10 mg prior to paclitaxel infusion. Copyright 2001 S. Karger GmbH, Freiburg

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455223     DOI: 10.1159/000055093

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  9 in total

1.  Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.

Authors:  Napa Parinyanitikul; Walailuk Tanpipattanakul; Nattaya Poovorawan; Thanapoom Rattananupong; Poranee Laoitthi; Piyada Sithidetphaiboon; Suebpong Thanasanvimon; Virote Sriuranpong
Journal:  Support Care Cancer       Date:  2018-02-12       Impact factor: 3.603

2.  Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.

Authors:  Michael J Berger; Craig Vargo; Mary Vincent; Katy Shaver; Gary Phillips; Rachel Layman; Erin Macrae; Ewa Mrozek; Bhuvaneswari Ramaswamy; Robert Wesolowski; Charles L Shapiro; Maryam B Lustberg
Journal:  Support Care Cancer       Date:  2014-12-18       Impact factor: 3.603

3.  Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis.

Authors:  Samuel Dubinsky; Deep Patel; Xiang Wang; Amirrtha Srikanthan; Terry L Ng; Corey Tsang
Journal:  Support Care Cancer       Date:  2022-02-12       Impact factor: 3.603

Review 4.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

5.  Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.

Authors:  Michael J Berger; Leslie J Dunlea; Amy E Rettig; Maryam B Lustberg; Gary S Phillips; Charles L Shapiro
Journal:  Support Care Cancer       Date:  2011-11-17       Impact factor: 3.603

6.  The added value of H2 antagonists in premedication regimens during paclitaxel treatment.

Authors:  Juul M Cox; Leni van Doorn; Ruben Malmberg; Esther Oomen-de Hoop; Tessa M Bosch; Patricia M L A van den Bemt; Ingrid A Boere; Agnes Jager; Ron H J Mathijssen; Roelof W F van Leeuwen
Journal:  Br J Cancer       Date:  2021-03-24       Impact factor: 9.075

7.  Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.

Authors:  J S Kloover; M A den Bakker; H Gelderblom; J P van Meerbeeck
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

8.  Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.

Authors:  Fu-Chao Chen; Lin-Hai Wang; Xiao-Yu Zheng; Xiu-Min Zhang; Jun Zhang; Lin-Jun Li
Journal:  Oncotarget       Date:  2017-03-21

9.  Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.

Authors:  Stefano D'Errico; Benedetta Baldari; Mauro Arcangeli; Alessandro Santurro; Paola Frati; Vittorio Fineschi
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.